Marks start of European commercial rollout of aXess™, bringing it into routine clinical practice Builds on CE mark approval in record time, underpinned by positive EU pivotal trial data Introduces a first-of-its-kind living vascular access solution for patients requiring hemodialysis EINDHOVEN, The Netherlands – 7 July, 2026 – Xeltis, a leading developer of transformative implants […]
US pivotal trial is a multi-center study evaluating a bioabsorbable hemodialysis vascular access implant across complex hemodialysis patients representing real-world practice > 50% of target enrollment reached across 20 sites in the United States EINDHOVEN, The Netherlands – 2 July, 2026 – Xeltis, a leading developer of transformative implants that enable the natural creation […]
Xeltis is one of only seven companies to successfully pass evaluation phase of EIC Strategic Technologies for Europe Platform (STEP) Scale Up call Funding to support commercialization of its groundbreaking bioresorbable vascular conduits EINDHOVEN, The Netherlands, 8 April 2025 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and […]
